Literature DB >> 15794855

Differential diagnosis of Waldenstrom's macroglobulinemia and other B-cell disorders.

Gerassimos A Pangalis1, Maria-Christina Kyrtsonis, Flora N Kontopidou, Marina P Siakantaris, Maria N Dimopoulou, Theodoros P Vassilakopoulos, Tatiana Tzenou, Styliani Kokoris, Evangelia Dimitriadou, Christina Kalpadakis, Kaliroe Tsalimalma, Panagiotis Tsaftaridis, Panagiotis Panayiotidis, Maria K Angelopoulou.   

Abstract

Waldenstrom's macroglobulinemia (WM) is characterized by lymphoplasmacytic infiltration of bone marrow and/or other tissues and by the presence of serum monoclonal immunoglobulin M ([IgM], without cutoff limit). Differential diagnosis from other B-cell disorders (BCDs) is usually easy based on clinical, morphologic, histopathologic, immunophenotypic, and genetic features. However, all BCDs potentially produce monoclonal IgM. In this study we reviewed the medical files of 130 patients with IgM-secreting BCDs. Eighty-four patients were diagnosed with WM, 5 with IgM-monoclonal gammopathy of undetermined significance (MGUS), and 41 with other BCDs (9 with B-cell chronic lymphocytic leukemia, 5 with small lymphocytic lymphoma, 14 with marginal zone lymphoma, 5 with mantle-cell lymphoma, 2 with follicular lymphoma, 2 with diffuse large B-cell lymphoma, 2 with cryoglobulinemia, and 2 with low-grade lymphoma not otherwise specified). Median IgM levels were 3215 mg/dL in WM, 840 mg/dL in IgM-MGUS, and 285 mg/dL in other BCDs (5 had IgM levels > 1500 mg/dL). In 10% of non-WM BCDs, monoclonal IgM was found only when more sensitive immunofixation methods were used. Forty-four percent of patients with BCDs (splenic marginal zone lymphoma or small lymphocytic lymphoma) had diagnoses that corresponded to that of WM. Careful diagnosis requires the concomitant evaluation of all parameters of BCDs together. Marginal zone lymphoma is the most frequently overlapping entity. Special attention should be given to mantle cell lymphoma in its atypical forms. Research in this field should continue to further clarify the disease entities that overlap with WM. New technology such as gene-expression profile techniques may contribute to this purpose.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15794855     DOI: 10.3816/clm.2005.n.006

Source DB:  PubMed          Journal:  Clin Lymphoma        ISSN: 1526-9655


  9 in total

1.  Genomewide linkage screen for Waldenstrom macroglobulinemia susceptibility loci in high-risk families.

Authors:  Mary L McMaster; Lynn R Goldin; Yan Bai; Monica Ter-Minassian; Stefan Boehringer; Therese R Giambarresi; Linda G Vasquez; Margaret A Tucker
Journal:  Am J Hum Genet       Date:  2006-08-31       Impact factor: 11.025

2.  Serum markers in the differential diagnosis of Waldenstrom macroglobulinemia and other IgM monoclonal gammopathies.

Authors:  Hong Zou; Rong Yang; Zhong-Xian Liao; Tian-di Qin; Ping Chen; Bei-Ying Zhang; Ying-Ping Cao; Hui-Fang Huang
Journal:  J Clin Lab Anal       Date:  2018-11-28       Impact factor: 2.352

3.  IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events.

Authors:  D Rizzo; J Chauzeix; F Trimoreau; J B Woillard; F Genevieve; A Bouvier; J Labrousse; C Poli; E Guerin; N Dmytruk; L Remenieras; J Feuillard; N Gachard
Journal:  Leukemia       Date:  2014-06-19       Impact factor: 11.528

4.  Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.

Authors:  Richard R Furman; Herbert A Eradat; Christine G DiRienzo; Craig C Hofmeister; Suzanne R Hayman; John P Leonard; Morton Coleman; Ranjana Advani; Asher Chanan-Khan; Julie Switzky; Qiming M Liao; Damini Shah; Roxanne C Jewell; Steen Lisby; Thomas S Lin
Journal:  Lancet Haematol       Date:  2016-12-01       Impact factor: 18.959

Review 5.  Update on therapeutic options in Waldenström macroglobulinemia.

Authors:  Xavier Leleu; Julie Gay; Aldo M Roccaro; Anne-Sophie Moreau; Stephanie Poulain; Remy Dulery; Berenice Bro Des Champs; Daniela Robu; Irene M Ghobrial
Journal:  Eur J Haematol       Date:  2009-01       Impact factor: 2.997

6.  Waldenstrom macroglobulinemia.

Authors:  Xavier Leleu; Aldo M Roccaro; Anne-Sophie Moreau; Sophie Dupire; Daniela Robu; Julie Gay; Evdoxia Hatjiharissi; Nicholas Burwik; Irene M Ghobrial
Journal:  Cancer Lett       Date:  2008-06-13       Impact factor: 8.679

7.  New insights into malignant B-cell disorders.

Authors:  Marie-Christine Kyrtsonis; Kazuyuki Shimizu; Panayiotis Panayiotidis; Gerassimos A Pangalis
Journal:  Biomed Res Int       Date:  2015-01-28       Impact factor: 3.411

Review 8.  Differential Diagnosis of Waldenström's Macroglobulinemia and Early Management: Perspectives from Clinical Practice.

Authors:  Shashank Cingam; Surbhi Sidana
Journal:  Blood Lymphat Cancer       Date:  2022-08-18

9.  Primary thymic mucosa-associated lymphoid tissue lymphoma complicated with renal amyloidosis: A first case report.

Authors:  Qin Chen; Yongjing Du; Singh Prince; Ping Zhang; Guisen Li; Li Wang; Wei Wang
Journal:  Medicine (Baltimore)       Date:  2020-03       Impact factor: 1.817

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.